Chen Miao-Fen, Chang Joseph Tung-Chieh, Tsang Ngan-Ming, Liao Chun-Ta, Chen Wen-Cheng
Department of Radiation Oncology, Chang Gung Memorial Hospital, Putz City, Chia-Yi, Taiwan.
Ann Otol Rhinol Laryngol. 2003 Oct;112(10):904-11. doi: 10.1177/000348940311201014.
This study is a retrospective analysis of 134 patients treated with radiotherapy at our hospital. The sample included 88 stage T1 and 46 stage T2 patients. Sixty-two patients had anterior commissure involvement, 37 patients had impaired vocal cord mobility, and 24 patients had supraglottic or subglottic extension. Irradiation was given, with the dose ranging from 60 to 72 Gy. Laryngectomy was the main salvage treatment for local recurrence. The 5-year initial and final local control rates were 71% and 83%, and the 10-year initial and final local control rates were 69% and 80%, comparable to the results of other series. The 5-year rate of overall survival with final larynx preservation was 77%. Multivariate analysis revealed that anterior commissure involvement is prognostic of a poor outcome in patients with T1 glottic cancer. Further subgroup analysis revealed that a fraction size of > 200 cGy could overcome the negative impact of anterior commissure involvement and significantly improve the 5-year local control rate in T1 patients (100% at > 200 cGy versus 45% at < or = 200 cGy; p = .04). Subglottic extension of the glottic cancer predicted poor outcome in T2 patients. The 5-year local control rates of patients with and without subglottic extension were 9% and 77%, respectively (p < .001). According to our results, radiotherapy with a fraction size of > 200 cGy is recommended for T1 disease with anterior commissure involvement. For patients with T2 disease and subglottic extension, radiotherapy alone produces poor results. Further improvement of outcomes by other treatment strategies needs to be investigated.
本研究是对我院134例接受放射治疗的患者进行的回顾性分析。样本包括88例T1期和46例T2期患者。62例患者有前联合受累,37例患者声带活动受限,24例患者有声门上或声门下扩展。照射剂量为60至72 Gy。喉切除术是局部复发的主要挽救治疗方法。5年初始和最终局部控制率分别为71%和83%,10年初始和最终局部控制率分别为69%和80%,与其他系列结果相当。最终保留喉功能的5年总生存率为77%。多因素分析显示,前联合受累是T1期声门癌患者预后不良的指标。进一步的亚组分析显示,分次剂量>200 cGy可克服前联合受累的负面影响,并显著提高T1期患者的5年局部控制率(分次剂量>200 cGy时为100%,分次剂量≤200 cGy时为45%;p = 0.04)。声门癌的声门下扩展预示T2期患者预后不良。有声门下扩展和无声门下扩展患者的5年局部控制率分别为9%和77%(p < 0.001)。根据我们的结果,对于有前联合受累的T1期疾病,推荐分次剂量>200 cGy的放射治疗。对于有T2期疾病和声门下扩展的患者,单纯放射治疗效果不佳。需要研究通过其他治疗策略进一步改善治疗结果。